Vascular Dynamics reports raising $10 million out of a hoped-for $23 million funding round for its MobiusHD anti-hypertension implant.
Vascular Dynamics said it raised nearly $10 million from a group of unnamed investors for the hypertension implant it's developing.
The Mountain View, Calif.-based startup reported raising $9.7 million in an offering of stock, warrants and other securities as part of a proposed $22.9 million funding round.
Sympara Medical quietly secures $5.5 million in funding from a handful of investors as it develops a device to treat hypertension.
Stealthy Sympara Medical quietly secured $5.5 million in funding from a handful of investors for the hypertension device it's developing.
San Francisco-based Sympara disclosed the funding in a regulatory filing, after recording $4.3 million with the SEC in 2013.
Ablative Solutions begins testing its infusion ablation catheter as a potential treatment for hypertension.
Another trial of Medtronic's Symplicity renal denervation device in treating hypertension shows no benefit compared with a sham procedure.
A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.
Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:
Medtronic's failed Symplicity HTN-3 renal denervation study doesn't look any better with 12 months of follow-up, according to new results presented at this year's European Society of Cardiology Congress.
Renal denervation technologies took another blow this week as 1-year results from Medtronic's (NYSE:MDT) much-lamented Symplicity HTN-3 trial still turned out no signs that the treatment is effective against hypertension.
The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.